SCYNEXIS
SCYX
#10067
Rank
โ‚น2.47 B
Marketcap
โ‚น58.90
Share price
-2.00%
Change (1 day)
-42.04%
Change (1 year)

P/E ratio for SCYNEXIS (SCYX)

P/E ratio as of December 2025 (TTM): -1.36

According to SCYNEXIS's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.36333. At the end of 2024 the company had a P/E ratio of -2.43.

P/E ratio history for SCYNEXIS from 2014 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-2.43-252.67%
20231.59-250.1%
2022-1.06-78.98%
2021-5.05257.1%
2020-1.4154.77%
2019-0.9134-52.99%
2018-1.94-21.28%
2017-2.4722.24%
2016-2.02-12.3%
2015-2.30-77.15%
2014-10.1

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Galmed Pharmaceuticals
GLMD
-0.2131-84.37%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
KemPharm
KMPH
-5.87 330.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Catalent
CTLT
-49.2 3,509.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Catalyst Pharmaceuticals
CPRX
12.9-1,049.07%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.